1940 results about "Hair loss" patented technology

The present invention relates to pharmaceutical compositions and formulations comprising a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia,osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; and / or e) decreasing the incidence of, halting or causing a regression of prostate cancer. The present invention provides pharmaceutical compositions comprising the selective androgen receptor modulator compounds, together with pharmaceutically acceptable excipients.

The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and / or other clinical therpauetic and / or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.

This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of acute and / or chronic muscular wasting conditions; e) preventing and / or treating dry eye conditions; f) oral androgen replacement therapy; and / or g) decreasing the incidence of, halting or causing a regression of prostate cancer.

A wearable hands-free apparatus for providing phototherapy treatment to a number of hair, scalp and skin related conditions includes a head unit (e.g., a headset, headphones, headband, or helmet unit) with earphones to allow the user to listen to an audio program during a treatment. The head unit supports a light emitting canopy band that is fitted with an array of light generating sources, such as light emitting diodes (LEDs), laser diodes, or infrared lights, that emit light within a particular wavelength range correlating with the treatment of one or more specific hair, scalp and / or skin-related conditions. The light emitting canopy band is specifically designed to conform to the shape of the human scalp for providing complete, uniform and consistent light coverage to the areas of the scalp that are most commonly affected by hair loss in men and women. A handheld control device allows the user to select the desired treatment program and is adapted for connection to a digital audio player device, such as an MP3 player, for delivering audio signals to the earphones.

The present invention includes 1) a novel formulation for the treatment of hair loss comprising oleanolic acid (a 5α-reductase inhibitor), apigenin (a vasodilator), and biotinyl-GHK (a cell metabolism stimulant), 2) a novel additive for the treatment of hair loss comprising oleanolic acid, apigenin, biotinyl-GHK and a delivery agent, 3) a personal care, cosmetic, and / or dermopharmaceutical composition comprising oleanolic acid, apigenin, biotinyl-GHK, and at least one additional ingredient, and 4) a method for treating hair loss comprising the administration of oleanolic acid, apigenin, and biotinyl-GHK.

This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are usefull for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of acute and / or chronic muscular wasting conditions; e) preventing and / or treating dry eye conditions; f) oral androgen replacement therapy; and / or g) decreasing the incidence of, halting or causing a regression of prostate cancer.

The invention belongs to the field of daily chemicals, in particular to a natural ferment liquid shampoo and a preparation method thereof. The problems of dandruff, hair oil, alopecia, withered and yellow hair and itchy scalps are solved. According to the technical scheme, the natural ferment liquid shampoo is prepared from, by weight, 15-20 parts of ginger, 15-20 parts of tea bran, 15-20 parts of Chinese honeylocust fruit, 15-20 parts of Chinese soapberry fruit, 10-20 parts of radix polygoni multiflori, 10-20 parts of Chinese arborvitae twigs, 15-20 parts of yerbadetajo herb, 5-10 parts of mulberry leaves, 15-20 parts of lemons, 15-20 parts of aloes, 10-20 parts of black beans, 10-20 parts of black sesame seeds, 15-20 parts of shrubalthea leaves, 1-1.5 parts of garden balsam stems, 1-1.5 parts of broadleaf holly leaves, 1-1.5 parts of white mulberry root-bark, 1-1.5 parts of honeysuckle stems, 1-1.5 parts of dried rehamnnia roots, 1-1.5 parts of milkvetch roots, 1-1.5 parts of radix angelica sinensis, 1-1.5 parts of glossy privet fruit, 1-1.5 parts of ginseng, 1-1.5 parts of roots of red-rooted salvia, 1-1.5 parts of ganoderma, 1,200-1,500 parts of washing water of rice, 120-150 parts of brown sugar and 0.01-0.03 part of probiotics. The natural ferment liquid shampoo has the effects of blacking hair, controlling oil, preventing hair loss, generating the hair, removing dandruff, diminishing inflammation, nourishing the hair and making the hair smooth.

The present invention relates to pharmaceutical compositions and formulations comprising a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; and / or e) decreasing the incidence of, halting or causing a regression of prostate cancer. The present invention provides pharmaceutical compositions comprising the selective androgen receptor modulator compounds, together with pharmaceutically acceptable excipients.

This invention provides androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of acute and / or chronic muscular wasting conditions; e) preventing and / or treating dry eye conditions; f) oral androgen replacement therapy; and / or g) decreasing the incidence of, halting or causing a regression of prostate cancer

Disclosed is a laser treatment device which is designed to stimulate hair growth and prevent hair loss by applying LLLT (Low Level Laser Therapy) to the scalp using laser light of a specified wavelength. The laser treatment device also provides ultra-low frequency mechanical vibrations to the scalp and the combination of light and vibrations is designed to produce synergy. Laser light, which may be blocked by remaining hair, may nonetheless reach the scalp using light-emitting elements attached to the ends of tooth-shaped protrusions. The present laser treatment device is characterised by a bendable applicator having said tooth-shaped protrusions such that it can change shape in accordance with the curvature of the head, which increase the efficiency of light and vibrational energy delivery. The laser treatment device is optimally controlled with a means to measure the light and vibrational energy supplied to the scalp, and the applicator may also be used as a wearable headset, which provide greater simplicity in mounting and removal.

A handheld head treatment device and method for reducing hair loss and stimulating hair growth by supplying current and laser light to a user's head. The device includes a current generator disposed within a housing configured to output a current for passage into the user's head and a laser source and guide means disposed within the housing configured to output and direct respective portions of the laser beam outward from the hair treatment device toward the user's head when the hair treatment device is in use. The method comprises the step of directing a series of different current and laser treatments to a portion of the scalp wherein the programmed current treatments are sequentially administered and include a continuous and pulsed direct current treatment.

A wearable hands-free apparatus for providing phototherapy treatment to a number of hair, scalp and skin related conditions includes a head unit (e.g., a headset, headphones, headband, or helmet unit) with earphones to allow the user to listen to an audio program during a treatment. The head unit supports a light emitting canopy band or plate fitted with an array of light generating sources, such as light emitting diodes (LEDs), laser diodes, infrared lights or other light sources, that emit light within a particular wavelength range correlating with the treatment of one or more specific hair, scalp and / or skin-related conditions. The light emitting canopy band or plate is specifically designed to conform to the shape of the human scalp for providing complete light coverage to the areas of the scalp that are most commonly affected by hair loss in men and women. In a further embodiment, a fixed or detachable face plate connects to the head unit and houses an array of the light generating sources for treating various facial skin-related conditions. A control system, preferably in a handheld device, allows the user to select the desired treatment program and audio operations.

This invention relates to compositions and processes for stimulating the growth of mammalian hair comprising the topical application of compositions comprising a hair growth stimulating and / or hair loss prevention agent, and a hair and / or skin lightening and / or neutralization agent, in association with a topical pharmaceutical carrier. Unlike other products, the composition of the invention can be used with dyed / treated hair so as to not affect the color of the hair.

Insulin sensitivity increasing substances (ISIS), including but not limited to D-chiro-inositol, thiazolidinedione and derivatives, and biguanides, are useful in the treatment of hair loss and other disorders of the pilosebaceous apparatus (hirsutism, acne, etc.) associated with conditions of excess insulin and / or insulin resistance. The treatment comprises administering to a mammal, such as a human, at least one ISIS either alone or in combination with at least one agent, such as an androgen receptor blocker (ARB) and / or a steroid enzyme inhibitor or inducer (STI). Additionally, an activity enhancing agent may be included for topical administration.

The present invention describes systems and methods for treating disorders and / or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and / or actinic keratosis. Methods generally involve administering nanoemulsions (e.g., nanoparticle compositions) comprising at least one therapeutic agent, such as botulinum toxin. In some embodiments, nanoemulsions are prepared, e.g., by high pressure microfluidization, and comprise a particle size distribution exclusively between 10 nm and 300 nm.

The present invention relates to the use of one or more tripeptides selected from the group consisting of NLys-Pro-ValC, NLys-Pro-ThrC and NpGLu-His-ProC for the reduction of oxidative stress. The above tripeptides are particularly useful for the treatment of a disease or damage caused by oxidative stress; such as vitiligo, scleroderma, necrosis, or erythema; furthermore, a disease or damage of the hair, like premature hair loss or premature formation of grey hair. Furthermore the invention relates the cosmetic use of the above tripeptides, in particular against skin aging. Further the invention relates cosmetic compositions containing at least one of said tripeptides.

The present invention describes systems and methods for treating disorders and / or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and / or actinic keratosis. Methods generally involve administering nanoemulsions (e.g., nanoparticle compositions) comprising at least one therapeutic agent, such as botulinum toxin. In some embodiments, nanoemulsions are prepared, e.g., by high pressure microfluidization, and comprise a particle size distribution exclusively between 10 nm and 300 nm.

The present invention is an orally- or topically-administrable composition for preventing and treating hair loss. The invention is a plant or plant extract containing isoflavones having a weak estrogen activity. The invention further includes methods for using the invented composition to prevent and treat hair loss.

The invention provides a light emitting device having an array of light emitting diodes (LED). The array of the device is arranged to illuminate a surface area of a scalp and the LEDs exhibit a plurality of wavelengths within the near infrared region of the electromagnetic spectrum between about 600-1000 nm, wherein the plurality of wavelengths synergistically combine to decrease follicular apoptosis. The array of light emitting diodes can include LEDs that are pulsed and can contain an array of light emitting diodes corresponding to about 30-200, preferably about 50-150, and more preferably about 80-120 LEDs. The light emitting device of the invention also can include a headband or a stationary mount or other mount for positioning over a target area. Also provided is a method of reducing follicular cell apoptosis. The method includes illuminating a surface area of a scalp containing a follicular hair cell for an effective period of time with an array of light emitting diodes (LED). The array of LEDs exhibit a plurality of wavelengths within the near infrared region of the electromagnetic spectrum between about 600-100 nm, wherein the plurality of wavelengths synergistically combine to decrease follicular cell apoptosis. The method can include inducing an increase in nitric oxide production compared to an untreated follicular hair cell as well as inducing mitochondrial chromophore activation. An effective period of time can include about 5-30 minutes, about 10-20 minutes or about 12-18 minutes and can promote vaso perfusion of the scalp or reduction in hair loss.

Disclosed is a method for managing obesity, diabetes, hair loss, aging, cardiovascular, or other blood glucose-spike-induced diseases by reducing the post-prandial blood glucose spike, or the glucose shock. The blood glucose spike, or the glucose shock is reduced by generating a person-specific glucose profile for at least one significant meal to tune or train a blood glucose model (kinetic, artificial intelligence or hybrid), and then using the tuned or the trained model embedded in a computation-capable electronic device to compute and recommend a person-specific meal plan and an exercise plan, including semi-continuous meal ingestion and post-meal exercise while sitting at home or office. Advantages over prior art are that the method uses less strenuous exercise with no or less medicine, is person-specific, quantitative and more suitable for use by an individual, a dietician, or a health care practitioner.

Substances, compositions and methods for hair treatment based on ultra-low molecular weight hyaluronic acid oligomers, possibly combined with trichogenic substances, useful for preventing hair loss and favouring its regrowth in subjects affected by androgenetic alopecia, alopecia areata, alopecia mucinosa and related disorders.

The present invention relates to hair growth compositions as well as to methods for treating hair loss or related conditions.

In one embodiment, this invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). The SARM compounds have unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. In one embodiment, the SARM compounds bind irreversibly to the androgen receptor In another embodiment, the SARM compounds are androgen receptor antagonists, which bind irreversibly to the androgen receptor. In another embodiment, the SARM compounds are alkylating agents. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of acute and / or chronic muscular wasting conditions; e) preventing and / or treating dry eye conditions; f) oral androgen replacement therapy; g) decreasing the incidence of, halting or causing a regression of prostate cancer; and / or h) inducing apoptosis in a cancer cell.

7-Oxo-DHEA derivatives, various of which are themselves novel compounds, are well suited for cosmetically / therapeutically treating adverse conditions / afflictions of a keratinous substrate / material, notably of human skin, hair, eyelashes and nails, to improve the appearance thereof, in particular to prevent or treat signs of aging of the skin and / or a dull complexion and / or skin or hair pigmentation disorders and / or dryness of the skin and / or hyperseborrhoea and / or hyperseborrhoea-related imperfections and / or sensitive skin and / or dandruff and / or natural hair loss and / or baldness.